Nectar Lifesciences posts Q3 FY26 results, details pharma business sale & buyback.
Nectar Lifesciences reported Q3 FY26 results after a board meeting on January 23, 2026. The company finalized the sale of its Pharma Business and Menthol Assets for ₹125,398.55 lakhs, recognizing an ₹8,815.13 lakhs profit. A sale of the Capsule Business for ₹1,990.00 lakhs is pending approval. A ₹8,100.00 lakhs share buyback was completed.
The announcement includes the completion of a significant business sale (Pharma and Menthol businesses) for a substantial consideration, and the completion of a share buyback. These are material events that will significantly impact the company's future financial structure and operations.
The announcement details the financial results and significant corporate actions like business sales and a completed share buyback. While these actions represent strategic shifts, the financial results themselves do not show a significant positive or negative trend without further context on profitability. The recognition of profit from exceptional items due to business sales is noted.
Nectar Lifesciences Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors noted, decided, and approved these results in a meeting held on January 23, 2026, which commenced at 3:00 PM IST and concluded at 4:30 PM IST.
The company has completed the sale of its Pharma Business (API and Formulation) and Menthol Assets to Ceph Lifesciences Private Limited for a total consideration of ₹127,000.00 lakhs, with a final adjusted consideration of ₹125,398.55 lakhs. A profit of ₹8,815.13 lakhs (net of tax) from this sale has been recognized under exceptional items. The sale of the Pharma Businesses was completed on November 10, 2025, with ₹106,598.55 lakhs received by December 31, 2025, and the balance ₹18,800.00 lakhs receivable.
Furthermore, Nectar Lifesciences entered into an agreement on December 20, 2025, to sell its Empty Hard Gelatin Capsule business to Capnest Health Care Private Limited for a consideration of ₹1,990.00 lakhs. This transaction is subject to government approval.
In a significant corporate action, the Board had previously approved a buyback proposal on December 3, 2025, for 3,00,00,000 equity shares at ₹27.00 per share, aggregating ₹8,100.00 lakhs. The payment for this buyback was made on January 13, 2026, and the shares were extinguished on January 20, 2026. As these events occurred after the financial reporting date, their impact is not reflected in the results for the quarter ended December 31, 2025.
The financial results reflect continuing operations, with figures for discontinued operations (Pharma Business, Menthol Assets, and Capsule Business) presented separately as per Ind AS 105.
What to do with a filing like this
Nectar Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under other results related. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nectar Lifesciences Limited. Read the original for the full detail.